Of interest, the combination of the two immunotherapies achieved better efficacy, a further decrease of tumor growth, and even complete regression and prolonged survival in the tumor-bearing mice were observed, which is attributed to the increased level of activated CD8+ cytotoxic T cells (GzmB+) infiltration in the tumors made by the combination therapy (Fig. 7k–p). This evidence concerns the gene CD8A and neoplasm.